Wall Street analysts remain bullish on Eli Lilly, boasting an Average Brokerage Recommendation (ABR) of 1.46, largely between ...

Eli Lilly is grabbing investor attention thanks to sharp earnings and revenue growth projections, though its Zacks Rank ...

Several major U.S. health insurers announce they will voluntarily speed up and simplify the prior authorization process.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

International Business News: Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 20 ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell ...

Risinger also lowered Eli Lilly's price target from $989 to $944 on the formulary news, calling it a negative in a note Thursday. Read more about Eli LIlly's stock moves and today's market action.

(Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker ...

Eli Lilly Downplays CVS Move to Drop Zepbound Coverage, Shares Plunge By Bhanvi Satija and Patrick Wingrove (Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's ...

US Stock Market Highlights: The S&P 500 rose 0.13% to close at 5,282.70 on Thursday (April 17) after a volatile trading session, though the index still ended the holiday-shortened week in the red amid ...